Angiogenic Gene Therapy for Refractory Angina: Results of the EXACT Phase 2 Trial.

ABSTRACT:

Background

XC001 is a novel adenoviral-5 vector designed to express multiple isoforms of VEGF (vascular endothelial growth factor) and more safely and potently induce angiogenesis. The EXACT trial (Epicardial Delivery of XC001 Gene Therapy for Refractory Angina Coronary Treatment) assessed the safety and preliminary efficacy of XC001 in patients with no option refractory angina.

Methods

In this single-arm, multicenter, open-label trial, 32 patients with no option refractory angina received a single treatment of XC001 (1×10¹¹ viral particles) via transepicardial delivery.

Results

There were no severe adverse events attributed to the study drug. Twenty expected severe adverse events in 13 patients were related to the surgical procedure. Total exercise duratio

SUBMITTER: Nakamura K 

PROVIDER: S-EPMC11097950 | biostudies-literature | 2024 May

REPOSITORIES: biostudies-literature